Led by Director and Principal Andrew Briggs, DPhil, and CEO John Schneider, PhD, AHE researchers and consultants have extensive knowledge and experience in the field of health economics and outcomes research (HEOR). These services include a wide variety of offerings across the product development continuum. In the early stages of development, we provide insights and analysis on potential market size and the design of rigorous economic evaluations, such as clinical studies and cost-effectiveness analysis. In later stages of development, we can offer more in-depth analyses to support expanded market access. For more information, view one of our past presentations on Establishing the Value of New Drugs, Devices, and Diagnostics.
Traditional HEOR has focused mainly on model building, utility development, and so on. But as data sources have become more nuanced and complex, and product value pathways have become more intricate, there is a need to push the limits of HEOR by applying state-of-the art statistical analyses of data. To address this need, Avalon has developed a practice area within its HEOR capability called HEOR Analytics. These tasks include novel statistical analyses of HEOR data, such as trial data or quality of life data, and novel applications of those analyses to statistical and economic models.
* Provided through a collaborative partnership with Acaster-Lloyd Consulting.
**For European markets, also provided through our collaborative partnership with Oberender.
Andrew Briggs Discusses the Economic Implications of PCSK9 Inhibitors in Clinical Practice:
Economic evaluation of passive monitoring technology for seniors. 2019
A decision-analytic model to assess the cost-effectiveness of etelcalcetide vs. cinacalcet. 2018
Enhancing the value of the ASCO value framework. 2018
High-Sensitivity Troponin T and Incident Heart Failure in Older Men: British Regional Heart Study. 2018
